News

Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Pulmonology Advisor1d
Enflonsia Approved for RSV Disease Prevention in Infants
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
Medindia on MSN1d
FDA Approves ENFLONSIA to Shield Infants From RSV
In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...
WTVR.com2d
FDA Approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
Clinical Trials Arena3d
MSD’s Enflonsia receives FDA approval for RSV prophylaxis
Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
New antibody shot could help protect babies from RSV
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
Fierce Pharma5d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
ABC Action News3d
FDA Approves Merck’s Enflonsia to prevent RSV in infants
The drug, Enflonsia, is a long-acting monoclonal antibody intended to prevent RSV-related lower respiratory tract disease in newborns and infants entering their first RSV season. RSV is a leading ...
Pharmaceutical Technology on MSN4d
MSD receives FDA approval for Enflonsia to prevent RSV
The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.